IMR Press / FBL / Volume 8 / Issue 4 / DOI: 10.2741/1140

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Fibrinolysis and diabetes
Show Less
1 Department of Medicine, University of Vermont College of Medicine, Burlington, VT, USA

Academic Editor: Karin Bornfeldt

Front. Biosci. (Landmark Ed) 2003, 8(4), 1085–1092;
Published: 1 September 2003
(This article belongs to the Special Issue Tachykinin-mediated modulation of the immune response)

Diabetes is characterized by impaired fibrinolysis. This phenomenon reflects augmented concentrations of plasminogen activator inhibitor type-1 in tissues and in blood. The derangement appears to depend in part on elevated concentrations of free fatty acids, triglycerides, and insulin in association with the insulin resistance syndrome. Impaired fibrinolysis may exacerbate already existing coronary artery disease and potentiate its evolution. Several measures are available to favorably modify fibrinolytic system capacity. They include inhibition of the renin angiotensin system, attenuation of dyslipidemia, and enhancement of insulin sensitivity. Accordingly, normalization of the derangement in fibrinolysis typical of diabetes is an important and achievable therapeutic objective.

Back to top